Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 known ✓ | Q04771 | 15/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 4/20 | 0.98 |
| ▸ | ACVR1B | P36896 | 14/20 | 0.98 |
| ▸ | BMPR1A | P36894 | 14/20 | 0.98 |
| ▸ | ACVRL1 | P37023 | 14/20 | 0.98 |
| ▸ | BMPR1B | O00238 | 12/20 | 0.98 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.98 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.98 |
| ▸ | BMPR2 | Q13873 | 4/20 | 0.98 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.98 |
| ▸ | BMP4 | P12644 | 4/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.98 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2059683 | 1.00 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL22462135 | 1.00 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL29373122 | 1.00 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL456393 | 0.99 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL29353046 | 0.99 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hypochlorous Acid SCHEMBL26968209 | 0.96 | ACVR1B (0.94) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| Hydrochloric Acid SCHEMBL30388107 | 0.93 | ACVR1 (0.98) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL24908393 | 0.93 | ACVR1B (0.89) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL16025991 | 0.92 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B | |
| SCHEMBL29391702 | 0.92 | ACVR1 (1.00) | ACVR1ACVR1BBMPR1AACVRL1BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064859-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-02-27 | — | — | US | claimed |
| EP-4493679-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2023178239-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-09-21 | — | — | WO | claimed |
| US-20260098246-A1 | COMPOSITIONS AND PROCESSES FOR ENGINEERING URETERIC BUD KIDNEY TISSUES AND IN-VITRO COMPOSITIONS THEREOF | TRESTLE BIOTHERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4714459-A1 | COMPOSITION FOR PREVENTING OR TREATING SALIVARY GLAND DISEASES, COMPRISING EPITHELIAL PROGENITOR CELLS OR STEM CELLS IN MINOR SALIVARY GLAND DUCT | UIF (University Industry Foundation), Yonsei University (KR) | 2026-03-25 | — | — | EP | disclosed |
| US-12584111-B2 | Compositions and methods for long term culture of hepatocytes | PEKING UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4698629-A1 | DERIVATION OF PRIMARY EPITHELIAL ORGANOIDS | UCL Business Ltd (GB) | 2026-02-25 | — | — | EP | disclosed |
| EP-4689063-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING RPE CELLS | Stemcell Technologies Canada Inc. (CA) | 2026-02-11 | — | — | EP | disclosed |
| EP-4602150-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Eyestem Research Private Limited (IN) | 2025-08-20 | — | — | EP | disclosed |
| US-20250241964-A1 | SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2025-07-31 | — | — | US | disclosed |
| CN-120019141-A | Scalable method for generating Retinal Pigment Epithelial (RPE) cells | 艾视泰研究私人有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024008810-A1 | DIFFERENTIATION OF STEM CELLS TO PANCREATIC ENDOCRINE CELLS | NOVO NORDISK A/S (DK) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023178239-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023150555-A1 | GENERATION OF BROWN ADIPOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023099554-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023090928-A1 | METHOD FOR ISOLATING, MAINTAINING, PROLIFERATING, AND DIFFERENTIATING MONOCLONAL CELLS DERIVED FROM HUMAN SALIVARY GLAND EPITHELIAL STEM CELLS OR PROGENITOR CELLS AND PRODUCTION METHOD FOR EXTRACELLULAR VESICLES FOR TREATING SALIVARY GLAND DISEASES | 연세대학교 산학협력단 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023054396-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | 住友化学株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2022266097-A1 | METHODS FOR GENERATING PARVALBUMIN-POSITIVE INTERNEURONS | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022258511-A1 | METHOD FOR GENERATING HIGHLY FUNCTIONAL HEPATOCYTES BY DIFFERENTIATING HEPATOBLASTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-12-15 | — | — | WO | disclosed |
| US-20220135941-A1 | COMPOSITIONS AND METHODS FOR LONG TERM CULTURE OF HEPATOCYTES | PEKING UNIVERSITY (CN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098246-A1 | COMPOSITIONS AND PROCESSES FOR ENGINEERING URETERIC BUD KIDNEY TISSUES AND IN-VITRO COMPOSITIONS THEREOF | PAX2, PAX3, PAXBP1 | ACVR1 397/4885KDR 309/4885ACVR1B 604/4885 |
| US-12584111-B2 | Compositions and methods for long term culture of hepatocytes | WNT3A, CTNNB1, WNT1 | ACVR1 15/4885KDR 3154/4885ACVR1B 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.